Karen McGuire, PhD, discusses TolaSure, a groundbreaking therapy targeting epidermolysis bullosa simplex, focusing on cellular repair and blister reduction.
Karen M. McGuire, PhD
Advertisement
Karen M. McGuire, PhD, is the CEO and founder of BioMendics.
Articles by Karen M. McGuire, PhD
BioMendics is advancing TolaSure in the TAMES-02 trial for EBS, aiming for rapid market access and potential expansion to other keratinopathies.
Karen McGuire, PhD, discusses innovative TolaSure for treating epidermolysis bullosa simplex, focusing on disease modification rather than symptom management.
Karen McGuire, PhD, discusses TAMES-02, a clinical trial evaluating TolaSure for Epidermolysis Bullosa Simplex.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Modern, Multi-Modal Approaches to Repigmentation in Patients with Vitiligo
2
Amlitelimab Demonstrates Efficacy With Every-12-Weeks Dosing in AD Trials
3
Phase 2 Trial Suggests Disease-Modifying Role for Bitopertin in EPP
4
Dual ITK/JAK3 Inhibition Shows Strong Preclinical Activity in Severe Alopecia Areata
5